Free tool
Drug Trial Radar: Hematology and blood cancers
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
70
Not yet recruiting, industry sponsors, Hematology and blood cancers, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting411
- Completed1,472
70 trials
Showing 1 to 25, recently updated first.
- S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c MutationNot yet recruiting
ServierIndustry
NCT07722312 · 80 participants (planned) · Start Feb 1, 2027 · Primary completion Aug 11, 2029
Drug: S243249 600mg; S243249 400mg and 2 more · For: Relapsed or Refractory Acute Leukemia; Relapsed or Refractory Acute Myeloid Leukemia
- A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AMLNot yet recruiting
TuHURA Biosciences, Inc.Industry
NCT07939971 · 55 participants (planned) · Start Dec 2026 · Primary completion Dec 2028
Drug: TBS-2025 · For: Acute Myeloid Leukemia
- Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDSPivotal-lookingNot yet recruiting
Kura Oncology, Inc.Industry
NCT07929740 · 126 participants (planned) · Start Oct 30, 2026 · Primary completion Feb 28, 2029
Drug: Ziftomenib; Ziftomenib and 2 more · For: Myelodysplastic Syndrome (MDS)/AML; Myeloid Leukemia, Acute
- A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, PK/PD Characteristics, and Efficacy of SCTB10Not yet recruiting
Sinocelltech Ltd.Industry
NCT07847697 · 12 participants (planned) · Start Nov 30, 2026 · Primary completion Jun 30, 2029
Drug: SCTB10; Placebo · For: Healthy Participants
Sites: Tianjin, China
- Study of Food Effects of VV261 Tablets in Healthy Trial ParticipantsNot yet recruiting
Vigonvita Life SciencesIndustry
NCT07927218 · 15 participants (planned) · Start Nov 9, 2026 · Primary completion Dec 30, 2026
Drug: VV261; VV261 and 1 more · For: Severe Fever With Thrombocytopenia Syndrome
Sites: Hefei, China
- A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal ImpairmentNot yet recruiting
Syndax PharmaceuticalsIndustry
NCT07923071 · 18 participants (planned) · Start Nov 2026 · Primary completion Jan 2030
Drug: Revumenib · For: Relapsed/Refractory (R/R) Hematologic Malignancies; Acute Leukemia; Refractory Leukemia and 1 more
- A Study of MBS314 for Injection in Participants With Relapsed/Refractory Multiple Myeloma.Not yet recruiting
Beijing Mabworks Biotech Co., Ltd.Industry
NCT07911748 · 78 participants (planned) · Start Nov 2026 · Primary completion Dec 2027
Drug: MBS314 for Injection · For: Multiple Myeloma
- Phase 1 Dose Escalation Study of RXIM002 in Autoimmune CytopeniasNot yet recruiting
RiboX Therapeutics Ltd.Industry
NCT07765966 · 27 participants (planned) · Start Feb 1, 2027 · Primary completion Jun 30, 2028
Drug: RXIM002 · For: Immune Thrombocytopenia (ITP)
- Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney DiseaseNot yet recruiting
Cajal Therapeutics Inc.Industry
NCT07901933 · 24 participants (planned) · Start Nov 2026 · Primary completion Oct 2027
Drug: Placebo; CTX001 and 1 more · For: Chronic Kidney Disease; Anemia
Sites: Gosford, Australia; St Leonards, Australia; Southport, Australia · 4 sites in all
- A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML PatientsNot yet recruiting
Cullinan Therapeutics Inc.Industry
NCT07722767 · 90 participants (planned) · Start Oct 15, 2026 · Primary completion Sep 30, 2027
Drug: CLN-049; Azacitidine and 1 more · For: AML (Acute Myeloid Leukemia)
Sites: Duarte, California; Miami, Florida; Atlanta, Georgia · 5 sites in all
- A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid TumorsNot yet recruiting
Medsyn Biopharma, LLCIndustry
NCT07899632 · 75 participants (planned) · Start Nov 2026 · Primary completion Aug 2029
Drug: MDSY-1240 · For: Triple-Negative Breast Cancer (TNBC); Gastric Cancer (GC); Gastric Cancer Adenocarcinoma Metastatic and 11 more
- A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic LeukemiaNot yet recruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07770698 · 30 participants (planned) · Start Dec 2026 · Primary completion Apr 30, 2030
Drug: sonrotoclax; Azacitidine and 2 more · For: Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; B-cell Acute Lymphoblastic Leukemia and 9 more
- Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic AnemiaNot yet recruiting
China Immunotech (Beijing) Biotechnology Co., Ltd.Industry
NCT07453836 · 13 participants (planned) · Start Nov 18, 2026 · Primary completion Mar 18, 2027
Drug: YTS109 cell · For: Autoimmune Hemolytic Anemia
Sites: Beijing, China
- REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)Not yet recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07887750 · 36 participants (planned) · Start Dec 7, 2026 · Primary completion Nov 1, 2029
Drug: REGN9220; Odronextamab · For: Diffuse Large B-Cell Lymphoma (DLBCL)
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07887646 · 70 participants (planned) · Start Dec 11, 2026 · Primary completion Oct 31, 2029
Drug: BG-T0920 · For: Diffuse Large B-Cell Lymphoma; B-cell Malignancies
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07881211 · 70 participants (planned) · Start Nov 30, 2026 · Primary completion Oct 31, 2029
Drug: BG-T0050 · For: Diffuse Large B-Cell Lymphoma; B-Cell Malignancies
- KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme MalignanciesPivotal-lookingNot yet recruiting
Stemline Therapeutics, Inc.Industry
NCT07873827 · 115 participants (planned) · Start Oct 30, 2026 · Primary completion May 12, 2028
Drug: MEN2312 · For: Hematological Malignancy
- Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38.Not yet recruiting
Great Novel Therapeutics Biotech & Medicals CorporationIndustry
NCT07842445 · 70 participants (planned) · Start Dec 1, 2026 · Primary completion Feb 28, 2029
Drug: GNTbm-38 · For: Solid Tumor (Phase I); Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Shanghai Simnova Biotechnology Co.,Ltd.Industry
NCT07830238 · 28 participants (planned) · Start Sep 2026 · Primary completion Mar 2030
Drug: SNC116 · For: B-cell Acute Lymphoblastic Leukemia
Sites: Changchun, China
- A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell LymphomaPivotal-lookingNot yet recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07818499 · 204 participants (planned) · Start Sep 2026 · Primary completion Dec 2028
Drug: BL-M08D1; Rituximab and 6 more · For: Diffuse Large B-Cell Lymphoma
Sites: Guangzhou, China; Suzhou, China
- SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin LymphomaNot yet recruiting
Sinocelltech Ltd.Industry
NCT07819188 · 90 participants (planned) · Start Sep 30, 2026 · Primary completion Sep 30, 2028
Drug: SCTB35 injection; SCTB41 · For: NHL - Non-Hodgkin's Lymphoma
Sites: Tianjing, China
Grit BiotechnologyIndustry
NCT07676006 · 36 participants (planned) · Start May 2027 · Primary completion Jun 2030
Drug: GT737 Injection · For: Relapsed/Refractory Acute Myeloid Leukemia (AML)
Sites: Shenzhen, China
- A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell LymphomaNot yet recruiting
FutureGen Biopharmaceutical (Beijing) Co., LtdIndustry
NCT07758491 · 110 participants (planned) · Start Aug 30, 2026 · Primary completion Jan 2031
Drug: FG-M131; FG-M131 · For: PTCL; TRBC1 ADC; CTCL
Sites: Beijing, China
- A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic SyndromesNot yet recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07591168 · 92 participants (planned) · Start Sep 2026 · Primary completion Dec 2028
Drug: BL-M11D1 · For: Myelodysplastic Syndromes
Sites: Tianjin, China
- A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple MyelomaNot yet recruiting
BrightPath Biotherapeutics Co., Ltd.Industry
NCT07667868 · 18 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 31, 2027
Drug: BP2202 · For: Relapsed/Refractory Multiple Myeloma (RRMM)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.